Indication intelligence, analysis and sector perception

BioTime (NYSE American: BTX) closes acquisition of Asterias Biotherapeutics (NYSE American: AST)

March 11, 2019 10:23am

BTX is UP +$0.055 or +4.198% to $1.365

BTX now has 151,579,482 M shares or 84% of the combined company, and prior Asterias stockholders collectively owning approximately 16% of the combined company

Post-closing, two members of the AST Board of Directors, Don Bailey, the former Chairman of Asterias’ Board and Michael Mulroy, the former CEO of Asterias will be serving on the BioTime Board of Directors. BioTime will continue to be led by the Company’s current management team.

Brian M. Culley, CEO of BTX stated “we expect to enjoy significant financial synergies from this merger as we already have a cGMP manufacturing facility in Jerusalem, Israel, which has successfully produced our projected needs for the next clinical trial of OpRegen® and which now can turn to process development and scale-up activities for the former Asterias assets. We also look forward to continuing our partnerships with notable institutions such as CIRM, the California Institute for Regenerative Medicine, and Cancer Research UK, to support the clinical development of the OPC1 and VAC2 programs we added to our pipeline.”

BioTime’s financial advisor in the transaction was Maxim Group LLC.
Raymond James acted as financial advisor to Asterias.
Cooley LLP served as legal counsel to BioTime and Dentons LLP served as legal counsel to Asterias

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 15 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.